As of Friday close, Halozyme Therapeutics Inc.’s (NASDAQ:HALO) stock was up $0.78, moving up 1.84 percent to $43.26. The average number of shares traded per day over the past five days has been 713,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.49 fall in that time frame. In the last twenty days, the average volume was 984,445, while in the previous 50 days, it was 1,103,610.
Since last month, HALO stock rose 1.62%. Shares of the company fell to $41.27 on 07/19/23, the lowest level in the past month. A 52-week high of $59.46 was reached on 01/03/23 after having rallying from a 52-week low of $29.85. Since the beginning of this year, HALO’s stock price has dropped by -23.97% or -$13.64, and marked a new high 1 time. However, the stock has declined by -27.25% since its 52-week high.
HALO stock investors should be aware that Halozyme Therapeutics Inc. (HALO) stock had its last reported insider trading activity 2 days ago on Aug 17. Torley Helen, the PRESIDENT AND CEO of the company, disposed of 10,000 shares for $43.18 on Aug 17. It resulted in a $431,820 divestment by the insider. Torley Helen sold 10,000 shares at an average price of $43.53 on Aug 16. The insider now owns 623,666 shares following the transaction. On Aug 15, PRESIDENT AND CEO Torley Helen sold 10,000 shares at $43.77 apiece. The transaction was valued at $437,680.
Valuation Metrics
Right now, Halozyme Therapeutics Inc. (HALO) has a P/E ratio of about 25.40. The stock’s beta is 1.23. Besides these, the trailing price-to-sales (P/S) ratio of 7.42, the price-to-book (PB) ratio of 37.62, and the price-to-cash flow ratio of 19.84 may also be considered.
Financial Health
In the three months ended June 29, Halozyme Therapeutics Inc.’s quick ratio stood at 5.40, while its current ratio was 6.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 9.91, and the total debt-to-equity ratio was 9.91. On the profitability front, the trailing twelve-month gross margin is 77.40% percent. In the year ended June 29, EBITDA margin amounted to 51.37%, whereas operating margins totaled 39.20%. Based on annual data, HALO earned $520.81 million in gross profit and brought in $660.12 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.00%. Return on equity (ROE) for the past 12 months was 193.30%.
In Halozyme Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $1.5 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HALO’s revenue rose 31.07% to $162.14 million during the quarter, while net income inched up to $221.04 million. While analysts expected Halozyme Therapeutics Inc. to report $0.63 quarterly earnings, the actual figure was $0.74 per share, beating the consensus estimate by 17.50%. During the quarter, the company generated $115.48 million in EBITDA. The liabilities of Halozyme Therapeutics Inc. were 1.66 billion at the end of its most recent quarter ended June 29, and its total debt was $1.53 billion. The value of shareholders’ equity is $131.92 million.
Technical Picture
This quick technical analysis looks at Halozyme Therapeutics Inc.’s (HALO) price momentum. With a historical volatility rate of 29.60%, the RSI 9-day stood at 54.85% on 18 August.
With respect to its five-day moving average, the current Halozyme Therapeutics Inc. price is down by -1.12% percent or -$0.49. At present, HALO shares trade +0.86% above its 20-day simple moving average and +21.18% percent above its 100-day simple moving average. However, the stock is currently trading approximately +24.60% above its SMA50 and -9.52% below its SMA200.
Stochastic coefficient K was 42.98% and Stochastic coefficient D was 52.21%, while ATR was 1.39. Given the Stochastic reading of 50.14% for the 14-day period, the RSI (14) reading has been calculated as 58.23%. As of today, the MACD Oscillator reading stands at -0.39, while the 14-day reading stands at -0.01.
Analyst Ratings
H.C. Wainwright launched its rating on Halozyme Therapeutics Inc. (NASDAQ: HALO) to a Buy in a note to investors on July 24, 2023.
With a median target price of $51.00, the current consensus forecast for the stock is $28.00 – $72.00. Based on these forecasts, analysts predict Halozyme Therapeutics Inc. (HALO) will achieve an average price target of $51.80.
